MediciNova Inc (MNOV)vsModerna Inc (MRNA)
MNOV
MediciNova Inc
$1.81
+4.02%
HEALTHCARE · Cap: $79.74M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 241948% more annual revenue ($2.23B vs $920,480). MNOV leads profitability with a 0.0% profit margin vs -141.4%. MNOV earns a higher WallStSmart Score of 30/100 (F).
MNOV
Avoid30
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MNOV.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 240.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MNOV
The strongest argument for MNOV centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 240.6% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MNOV
The primary concerns for MNOV are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MNOV profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MNOV is growing revenue faster at 240.6% — sustainability is the question.
MRNA generates stronger free cash flow (-563M), providing more financial flexibility.
Bottom Line
MNOV scores higher overall (30/100 vs 21/100) and 240.6% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MediciNova Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapies for the treatment of serious diseases with unmet medical needs in the United States. The company is headquartered in La Jolla, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?